Welcome to CBA Pharma, Inc. The unifying principle of "Many Minds, One Heart"® is the core of the philosophical foundation of CBA Pharma.  It best reflects the pioneering research and product development success acheived over the past decades leading to the creation of this company.  It signifies the focused intent of many individuals (employees, shareholders, consultants, clinical investigators, etc.) toward a commnon vision.

CBA Pharma's vision is to provide hope and opportunity for a normal life span with an improved quality of life to people with life threatening disease.

CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be a potentially effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, is being developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.